###begin article-title 0
###xml 36 42 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 43 46 43 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/4</italic>
###xml 19 26 <span type="species:ncbi:9606">Patient</span>
A Case Report of a Patient Carrying CYP2C9*3/4 Genotype with Extremely Low Warfarin Dose Requirement
###end article-title 0
###begin p 1
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 108 110 108 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/</italic>
###xml 111 112 111 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 421 427 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 470 476 470 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 477 479 477 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/</italic>
###xml 480 481 480 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 534 541 534 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9*</italic>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 and </italic>
###xml 548 549 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 88 95 <span type="species:ncbi:9606">patient</span>
###xml 126 131 <span type="species:ncbi:9606">woman</span>
###xml 447 454 <span type="species:ncbi:9606">patient</span>
We report a case of intolerance to warfarin dosing due to impaired drug metabolism in a patient with CYP2C9*3/*4. A 73-yr-old woman with atrial fibrilation was taking warfarin. She attained a high prothrombin time international normalized ratio (INR) at the standard doses during the induction of anticoagulation and extremely low dose of warfarin (6.5 mg/week) was finally chosen to reach the target INR. Genotyping for CYP2C9 revealed that this patient had a genotype CYP2C9*3/*4. This is the first Korean compound heterozygote for CYP2C9*3 and *4. This case suggests the clinical usefulness of pharmacogenetic testing for individualized dosage adjustments of warfarin.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 232 239 <span type="species:ncbi:9606">patient</span>
###xml 413 420 <span type="species:ncbi:9606">patient</span>
Warfarin therapy is problematic due to a narrow therapeutic index and frequent bleeding complications (1-5). Due to the significant interpatient variability for warfarin sensitivity, estimation of the optimal warfarin dose for each patient is difficult. The prolongation of the prothrombin time (PT) remains the primary way to measure the anticoagulant effect of warfarin. Therapy is individualized by monitoring patient's international normalized ratio (INR) of PT.
###end p 3
###begin p 4
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 309 315 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 361 362 361 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
Warfarin metabolism is catalyzed by CYP2C9, which metabolizes S-wafarin to inactive S-7-hydroxywarfarin (4). A genetic polymorphism of CYP2C9 contributes to the variability among patients for the required maintenance doses of warfarin (4). Multiple studies have clearly demonstrated an increased frequency of CYP2C9 allelic variants such as CYP2C9*2 and CYP2C9*3 in patients stabilized on low-dose warfarin therapy. A relationship has been established between genetic deficiency of the CYP2C9 enzyme activity and increased likelihood of extremely elevated INRs and major bleeding events, compared to the general population (6-11).
###end p 4
###begin p 5
###xml 85 91 85 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 92 94 92 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/</italic>
###xml 95 96 95 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 59 66 <span type="species:ncbi:9606">patient</span>
In this report, we present a case of warfarin therapy in a patient with the genotype CYP2C9*3/*4, which resulted in decreased activity of CYP2C9. Prolonged PT during the induction phase of standard warfarin therapy was found and a marked reduction of warfarin dosage was required to get to the target INR in this case.
###end p 5
###begin title 6
CASE REPORT
###end title 6
###begin p 7
###xml 12 17 <span type="species:ncbi:9606">woman</span>
###xml 136 143 <span type="species:ncbi:9606">patient</span>
A 73-yr-old woman with atrial fibrillation presented to the emergency room complaining of chest discomfort, dyspnea, and agitation. The patient had suffered from atrial fibrillation for the last 2 yr. Her medications for the previous 2 yr included diltiazem 90 mg, metoprorol 25 mg, and aspirin 100 mg twice a day. In addition, she had been taking mirtazapine 30 mg, alprazolam 0.25 mg, and zolpidem 10 mg daily for a 6 yr history of dysthymia.
###end p 7
###begin p 8
Physical examination showed a blood pressure of 100/83 mmHg, a heart rate of 100 beats/min, and a normal body temperature. Her body weight was 62.3 kg, and she was 158 cm in height. Initial laboratory results were unremarkable with a normal PT of 12.3 sec (INR 1.0). Routine chemical studies indicated normal values for total protein (6.6 g/dL), albumin (3.9 g/dL), aspartate aminotransferase (17 U/L), alanine aminotransferase (10 U/L), alkaline phosphatase (79 U/L), total bilirubin (0.3 mg/dL) blood urea nitrogen (16.4 mg/dL), creatinine (0.6 mg/dL), and electrolytes. Results of hematological studies including complete blood counts were also normal. Mild cardiomegaly was found on the chest radiography. Electrocardiogram showed atrial fibrillation. Echocardiogram revealed mild aortic, mitral, and tricuspid regurgitation and left atrial enlargement (45 mm).
###end p 8
###begin p 9
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 147 154 <span type="species:ncbi:9606">patient</span>
###xml 433 440 <span type="species:ncbi:9606">patient</span>
The patient underwent heparinization with an initial bolus administration of 3,600 IU heparin followed by continuous infusion for 6 days. Then the patient was started on 2 or 3 mg of warfarin daily (16.3 mg/week) to prevent thromboembolism, and was discharged after 3 days with a PT of 37.4 sec (INR 2.81). When she revisited the outpatient clinic after 3 days, her PT was found to be 50.0 sec (INR 3.68). After normalization of the patient's PT with warfarin withdrawal for 3 days, 1 or 2 mg/day (10.5 mg/week) of warfarin was prescribed. The PT after 3 days of treatment was 41.6 sec (INR 3.11). The administration of warfarin dose was changed (6.5-10.5 mg/week) continuously, which resulted in a PT of 20.9-43.1 sec (INR 1.64-3.21). She had to discontinue warfarin therapy temporarily 3 times. The difficulty in finding the optimal treatment dose during the induction period of anticoagulation continued for more than 2 month.
###end p 9
###begin p 10
###xml 4 11 <span type="species:ncbi:9606">patient</span>
The patient continues to receive warfarin therapy at the outpatient clinic monthly and her PT remains within the recommended target therapeutic range (INR 2.0-3.0), even though her warfarin dose has been reduced to 6.5 mg/week.
###end p 10
###begin p 11
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 422 428 422 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 429 431 429 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/</italic>
###xml 432 433 432 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 435 441 435 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 349 356 <span type="species:ncbi:9606">patient</span>
The patient was genotyped for CYP2C9 after informed consent. DNA was isolated from peripheral blood, and all 9 exons of the CYP2C9 gene were amplified by PCR (11-13). The PCR products were sequenced using the ABI PRISIM BigDye terminator Cycle sequencing kit and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, U.S.A.). The patient was found to be an intermediate metabolizer with the genotype of CYP2C9*3/*4 (Fig. 1).
###end p 11
###begin title 12
DISCUSSION
###end title 12
###begin p 13
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 116 117 116 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 156 162 156 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 122 130 <span type="species:ncbi:9606">Patients</span>
Genetic polymorphisms of CYP2C9 bring about a significant variability among individuals in regard to drug response (1-4). Patients with genetic variants of CYP2C9 are very sensitive to warfarin, and may become overanticoagulated on a standard dose.
###end p 13
###begin p 14
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 135 141 135 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 142 143 142 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 383 389 383 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 500 506 500 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 507 508 507 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 539 540 539 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 597 603 597 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 604 605 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 660 666 660 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 667 668 667 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 764 770 764 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 811 817 811 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 818 819 818 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 981 982 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 984 985 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1062 1068 1062 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1124 1130 1124 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 846 854 <span type="species:ncbi:9606">patients</span>
More than 20 variant alleles of CYP2C9 have been reported (14). Previous studies have demonstrated that 2 common variants CYP2C9*2 and CYP2C9*3 are associated with a reduced catalytic activity of CYP2C9 (1-11). Therefore, subjects who are homo- or heterozygous for these variant alleles require reduced maintenance doses for CYP2C9 substrates such as warfarin. Allele frequencies of CYP2C9 variants have been shown to be markedly different among populations. Caucasians possess higher frequencies of CYP2C9*3 than Asians (6-10% vs. 2-5%) (1-3). There have been no documented Asian carriers of the CYP2C9*2 variant, while 8-20% of Caucasians appear to have the CYP2C9*2 allele (1-11). Yoon et al. reported that from a pool of 574 Koreans 2.3% were heterozygous for CYP2C9*3 and none were found to be carriers of CYP2C9*2 (15). Caucasian and Asian patients require different warfarin dosages to achieve therapeutic anticoagulation and Asians appear to be more sensitive to warfarin (2, 9). This can only be partly explained by the 2 most common variant alleles of CYP2C9 in Caucasians, and there is a possibility that unknown CYP2C9 alleles exist in Asians.
###end p 14
###begin p 15
###xml 54 60 54 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 61 63 61 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/</italic>
###xml 64 65 64 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 100 106 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 107 108 107 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 208 214 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 242 243 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 255 256 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 37 44 <span type="species:ncbi:9606">patient</span>
This is the first report of a Korean patient with the CYP2C9*3/*4 showing warfarin intolerance. The CYP2C9*4 allele including 1076T>C (Ile359Thr) has been reported in only one Japanese subject (16). However, CYP2C9 variants other than CYP2C9*2 and CYP2C9*3 have not been studied in the Korean population. In addition, there has been no reported Korean subject identified as a compound heterozygote for the 2 variant alleles of CYP2C9.
###end p 15
###begin p 16
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 192 193 192 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 196 197 196 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 204 205 204 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</italic>
###xml 345 347 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 439 445 439 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 446 447 446 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 523 529 523 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 530 531 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 598 604 598 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1010 1016 1010 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1017 1018 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 1048 1054 1048 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1055 1056 1055 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</italic>
###xml 1061 1067 1061 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 1068 1069 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</italic>
###xml 1213 1215 1213 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 680 688 <span type="species:ncbi:9606">patients</span>
###xml 710 717 <span type="species:ncbi:9606">patient</span>
The functional significance of the CYP2C9*4 allele remains unclear. However, it is assumed that this allele causes significant reduction in the CYP2C9 enzyme activity. It is known that CYP2C9*3, *4, and *5 alleles all lie in a putative substrate recognition site, thus providing an explanation for their effects on the Km for CYP2C9 substrates (17). The position of 1076T>C (Ile359Thr) substitution is just close to 1075A>C (Ile359Leu) in CYP2C9*3, which causes decreased enzyme activity. Therefore, 1076T>C (Ile359Thr) in CYP2C9*4 is likely to affect the enzyme activity as 1075A>C (Ile359Leu) in CYP2C9*3 (16). While the usual maintenance dose of warfarin is 4-6 mg/day in most patients (28-42 mg/week), our patient required extremely low doses of warfarin (0.5 or 1 mg/day, 6.5 mg/week) to meet the target INR, suggesting a poor metabolizer phenotype with 2 functionally deficient alleles, rather than an intermediate metabolizer phenotype with 1 deficient allele. Gage et al. reported that homozygotes for CYP2C9*3 or compound heterozygotes of CYP2C9*3 and CYP2C9*2 had an average daily maintenance warfarin dose of 1.5 mg and 2.0 mg, respectively, compared to a daily maintenance dose of 5.1 mg in wildtype (18).
###end p 16
###begin p 17
###xml 45 46 45 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
According to the Korean study of Lee et al. (5), 83 patients visited emergency center for 2 yr due to the bleeding complications or high INR related to warfarin therapy. Lee et al. reported that one of the main reasons for non-therapeutic INRs was inadequate dosage adjustment (19) and suggested a dosing guideline for Korean outpatients with prosthetic heart valves (20). However, the current warfarin dosing algorithms still do not incorporate genetic factors that could affect warfarin dose requirements.
###end p 17
###begin p 18
###xml 4 11 <span type="species:ncbi:9606">patient</span>
###xml 125 132 <span type="species:ncbi:9606">patient</span>
###xml 451 458 <span type="species:ncbi:9606">patient</span>
Our patient attained a high INR at standard doses and might be at a higher risk for developing severe complications. In this patient, we could not identify any specific pharmacokinetic or pharmacodynamic factors associated with the warfarin response, such as drug interactions or underlying disease conditions. Therefore, a pharmacogenetic test was performed to explore the possible genetic factors contributing to the unusual warfarin response. This patient could have taken appropriate therapeutic measures earlier, and be maintained on a safer regimen with lower doses, if she had been genotyped at the beginning of warfarin therapy.
###end p 18
###begin p 19
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 426 427 426 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 429 430 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 165 173 <span type="species:ncbi:9606">patients</span>
The CYP2C9 genotype is associated with a risk of overanticoagulation and bleeding complications. Previous studies have suggested that a variant group, compared with patients with the wild-type genotype, require a higher rate of above-range INR, longer time to reach a therapeutic INR, smaller maintenance doses, longer time to stable warfarin dosing, longer hospitalization, and a higher risk of serious bleeding events (1-4, 6, 7, 11).
###end p 19
###begin p 20
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
CYP2C9 genotyping is recommended to complement PT monitoring especially when unusual metabolic activity of warfarin is suspected. Moreover, CYP2C9 genotyping before the initiation of therapy may serve as an important guide for more rapid dosage adjustment and prediction of drug response in each individual in the future.
###end p 20
###begin p 21
###xml 72 109 72 109 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ministry of Health &amp; Welfare, R. O. K</funding-source>
###xml 111 133 111 133 <award-id xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">03-PJ10-PG13-GD01-0002</award-id>
This study was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health & Welfare, R. O. K (03-PJ10-PG13-GD01-0002).
###end p 21
###begin article-title 22
Clinical consequences of cytochrome P450 2C9 polymorphisms
###end article-title 22
###begin article-title 23
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
###end article-title 23
###begin article-title 24
Pharmacogenetics of warfarin elimination and its clinical implications
###end article-title 24
###begin article-title 25
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
###end article-title 25
###begin article-title 26
###xml 18 26 <span type="species:ncbi:9606">patients</span>
Warfarin toxicity patients in the Emergency Department
###end article-title 26
###begin article-title 27
Pharmacogenetics of oral anticoagulants
###end article-title 27
###begin article-title 28
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
###end article-title 28
###begin article-title 29
###xml 72 80 <span type="species:ncbi:9606">patients</span>
The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin
###end article-title 29
###begin article-title 30
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
###end article-title 30
###begin article-title 31
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance
###end article-title 31
###begin article-title 32
###xml 78 83 <span type="species:ncbi:9606">human</span>
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data
###end article-title 32
###begin article-title 33
###xml 24 29 <span type="species:ncbi:9606">human</span>
Genetic analysis of the human cytochrome P450 CYP2C9 locus
###end article-title 33
###begin article-title 34
Allelic and functional variability of cytochrome P4502C9
###end article-title 34
###begin article-title 35
Frequency of cytochrome P450 2C9 mutant alleles in a Korean population
###end article-title 35
###begin article-title 36
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus
###end article-title 36
###begin article-title 37
Use of pharmacogenetics to guide warfarin therapy
###end article-title 37
###begin article-title 38
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
###end article-title 38
###begin article-title 39
Analysis of factors affecting nontherapeutic INRs in Korean outpatients with mechanical heart valves
###end article-title 39
###begin article-title 40
Determination of practical dosing of warfarin in Korean outpatients with mechanical heart valves
###end article-title 40
###begin p 41
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 90 96 90 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CYP2C9</italic>
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3/</italic>
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</italic>
###xml 77 84 <span type="species:ncbi:9606">patient</span>
Detection of nucleotide changes by sequencing analysis of CYP2C9 gene in the patient with CYP2C9*3/*4 showing A1075C (Ile359Leu) and A1076T (Ile359Thr) substitutions (indicated by arrows).
###end p 41

